NPX125 / NextPoint - LARVOL DELTA

NPX125, a novel ADC targeting B7-H7, shows potent activity in solid tumors (AACR-NCI-EORTC 2025) - "Incucyte® imaging analyses in HER2 positive cell line SKBR3 showed faster internalization compared to Trastuzumab-Dxd. Collectively, these preclinical studies establish B7-H7 as an attractive ADC target and demonstrate significant anti-tumor activity of a B7-H7 targeting ADC, NPX125, across different levels of B7-H7 expression on tumor cells. The data presented here supports clinical development of NPX125 as a promising treatment strategy."

Gastric Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • HER-2 • HHLA2

NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025 (Businesswire) - "NPX125, which utilizes NextPoint's proprietary linker technology paired with a clinically validated topoisomerase 1 inhibitor payload in a DAR8 (drug-antibody ratio) format, is initiating IND-enabling work with an anticipated IND filing in mid-2026....NPX125 via its interaction with B7-H7 demonstrated efficient internalization across many different tumor cell lines; Showed both direct and bystander cytotoxic activity, critical for addressing tumor heterogeneity; NPX125 demonstrated superior serum stability in rat pharmacokinetic studies; Robust developability profile due to antibody selection and unique linker properties....NextPoint will also present three additional posters at AACR showcasing its comprehensive approach to targeting the B7-H7 axis."

IND • Preclinical • Solid Tumor